Columbia University
Irving Medical Center
Neurological Institute
710 West 168th Street, 3rd floor
(212) 305-1818


TaubCONNECT Research Perspective:
May 2025
APOE and Alzheimer's Disease and Related Dementias Risk Among 12,221 Hispanics/Latinos
A Human Brain Map of Mitochondrial Respiratory Capacity and Diversity
ANXA11 Biomolecular Condensates Facilitate Protein-Lipid Phase Coupling on Lysosomal Membranes
Axonal Transport of CHMP2b Is Regulated by Kinesin-Binding Protein and Disrupted by CHMP2bintron5
Sleep Genetics and Cognitive Changes over Time: The Moderating Effect of Age and the Role of Brain
Emerging Roles for Tubulin PTMs in Neuronal Function and Neurodegenerative Disease
Inflammatory Biomarkers Profiles and Cognition Among Older Adults
Synaptic and Cognitive Impairment Associated with L444P Heterozygous Glucocerebrosidase Mutation
Regulation of Synapse Density by Pumilio RNA-Binding Proteins
CD33 and SHP-1/PTPN6 Interaction in Alzheimer's Disease
Cellular Communities Reveal Trajectories of Brain Ageing and Alzheimer's Disease
Epigenetic and Genetic Risk of Alzheimer Disease from Autopsied Brains in two Ethnic Groups
Multi-Omic Analysis of Huntington's Disease Reveals a Compensatory Astrocyte State
Design and Methods of the Early Age-Related Hearing Loss Investigation Randomized Controlled Trial
Updated Safety Results From Phase 3 Lecanemab Study in Early Alzheimer's Disease
The Broken Alzheimer's Disease Genome
Rare Genetic Variation in Fibronectin 1 (FN1) Protects Against APOEε4 in Alzheimer's Disease
Cell Subtype-Specific Effects of Genetic Variation in the Alzheimer's Disease Brain
Diet, Pace of Biological Aging, and Risk of Dementia in the Framingham Heart Study
A Comparative Study of Structural Variant Calling in WGS from Alzheimer's Disease Families
Glucocorticoid Stress Hormones Stimulate Vesicle-Free Tau Secretion and Spreading in the Braint
The Effects of Insufficient Sleep and Adequate Sleep on Cognitive Function in Healthy Adults
ZCCHC17 Modulates Neuronal RNA Splicing and Supports Cognitive Resilience in Alzheimer's Disease
Effects of Lithium on Serum Brain-Derived Neurotrophic Factor in Alzheimer's Patients with Agitation
2023 Taub Institute Grants for Emerging Research (TIGER) Awardees!
Rie1 and Sgn1 Form an RNA-Binding Complex that Enforces the Meiotic Entry Cell Fate Decision
Memory and Language Cognitive Data Harmonization Across the United States and Mexico
Education as a Moderator of Help Seeking Behavior in Subjective Cognitive Decline
Multicellular Communities are Perturbed in the Aging Human Brain and Alzheimer's Disease
The Neuropathological Landscape of Hispanic and non-Hispanic White Decedents with Alzheimer Disease
The Early-Onset Alzheimer's Disease Whole-Genome Sequencing Project: Study Design and Methodology
Polygenic Risk Score Penetrance & Recurrence Risk in Familial Alzheimer Disease
High School Quality is Associated with Cognition 58 Years Later
Glucocorticoid-Driven Mitochondrial Damage Stimulates Tau Pathology
A Global View of the Genetic Basis of Alzheimer Disease
ARIA in Patients Treated with Lecanemab (BAN2401) in a Phase 2 Study in Early Alzheimer's Disease
Microglia Reactivity Entails Microtubule Remodeling from Acentrosomal to Centrosomal Arrays
Genuine Selective Caspase-2 Inhibition with new Irreversible Small Peptidomimetics
Cell Type-Specific Changes Identified by Single-Cell Transcriptomics in Alzheimer's Disease
Brain Aging Among Racially and Ethnically Diverse Middle-Aged and Older Adults
First Place: Neuroproteasome Localization and Dysfunction Modulate Pathology in Alzheimer's Disease
Clearance of an Amyloid-Like Translational Repressor is Governed by 14-3-3 Proteins
Diet Moderates the Effect of Resting State Functional Connectivity on Cognitive Function
Retromer Deficiency in Tauopathy Models Enhances the Truncation and Toxicity of Tau
Progranulin Mutations in Clinical and Neuropathological Alzheimer's Disease
Wolframin is a Novel Regulator of Tau Pathology and Neurodegeneration
Homotypic Fibrillization of TMEM106B Across Diverse Neurodegenerative Diseases
Correlation of Plasma and Neuroimaging Biomarkers in Alzheimer's Disease
Tubulin Tyrosination Regulates Synaptic Function and is Disrupted in Alzheimer's Disease
The Penalty of Stress - Epichaperomes Negatively Reshaping the Brain in Neurodegenerative Disorders
The Neuronal Retromer can Regulate Both Neuronal and Microglial Phenotypes of Alzheimer's Disease
Deep Learning Improves Utility of Tau PET in the Study of Alzheimer's Disease
Age of Onset of Huntington's Disease in Carriers of Reduced Penetrance Alleles
Caspase-9: A Multimodal Therapeutic Target With Diverse Cellular Expression in Human Disease
Midlife Vascular Factors and Prevalence of Mild Cognitive Impairment in Late-Life in Mexico
The Association Between Sex and Risk of Alzheimer's Disease in Adults with Down Syndrome
Marked Mild Cognitive Deficits in Humanized Mouse Model of Alzheimer's-Type Tau Pathology
Rapid ATF4 Depletion Resets Synaptic Responsiveness after cLTP
Polygenic Risk Score for Alzheimer's Disease in Caribbean Hispanics
Recognition Memory and Divergent Cognitive Profiles in Prodromal Genetic Frontotemporal Dementia
The Microtubule Cytoskeleton at the Synapse & The Synaptic Life of Microtubules
Optimizing Subjective Cognitive Decline to Detect Early Cognitive Dysfunction
The AD Tau Core Spontaneously Self-Assembles and Recruits Full-Length Tau to Filaments
Olfactory Impairment is Related to Tau Pathology and Neuroinflammation in Alzheimer's Disease
Pathogenic Role of Delta 2 Tubulin in Bortezomib-Induced Peripheral Neuropathy
2: Selective Removal of Astrocytic PERK Protects Against Glymphatic Impairment and Decreases Toxic Aggregation of β-Amyloid and Tau
3: APOE ε4-Associated Heterogeneity of Neuroimaging Biomarkers Across the Alzheimer's Disease Continuum
![]() |
![]() |
Vilas Menon, PhD | Philip L. De Jager, MD, PhD |
111111 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
111111 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
111111 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Vilas Menon, PhD
Assistant Professor of Neurological Sciences (in Neurology and the Taub Institute)
vm2545@cumc.columbia.edu
Philip L. De Jager, MD, PhD
Weil-Granat Professor of Neurology(in The Taub Institute)
pld2115@cumc.columbia.edu

![]() | ![]() | ![]() | ||
Kai Chen, PhD | Tal Nuriel, PhD | Osama Al Dalahmah, MD, PhD |
2222222 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
2222222 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
2222222 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
2222222 Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Kai Chen, PhD
Associate Research Scientist in the Department of Anesthesiology
kc3378@cumc.columbia.edu
Tal Nuriel, PhD
Assistant Professor of Pathology and Cell Biology (in the Taub Institute) at CUMC
tn2283@cumc.columbia.edu
Osama Al Dalahmah, MD, PhD
Assistant Professor in Pathology and Cell Biology
oa2298@cumc.columbia.edu

APOE4-Associated Heterogeneity of Neuroimaging Biomarkers Across the Alzheimer's Disease Continuum
![]() | ![]() | |
Tal Nuriel, PhD | Osama Al Dalahmah, MD, PhD |

Figure 1. APOE ε4āassociated differences by diagnostic group. We performed linear mixedāeffects analyses comparing regional neuroimaging biomarker levels between APOE ε4 carriers versus nonācarriers, classified into one of three diagnostic groups: CN, MCI, or AD participants. Regions with significantly different biomarker levels (p ‹ 0.05) between the APOE ε4 carriers and nonācarriers in each diagnostic group were graphed onto box plots with two of the top regions labeled (A). We also rendered the regions onto a human brain template (displayed axially, coronally, and sagittally) using different shades of red (upregulated in APOE ε4 carriers) or blue (downregulated in APOE ε4 carriers) that corresponds to the magnitude of their statistical difference (beta) between APOE ε4 carrier groups (B)ā(F). We show the rendered biomarker differences from each analysis that resulted in at least one statistically different region, which in this diagnostic groupālevel comparison included Aβ PET results (B), tau PET results (C), FDG PET results (D), structural MRI results (E), and FLAIR MRI WMH results (F). Aβ, amyloid beta; AD, Alzheimer's disease; APOE, apolipoprotein E; ASL, arterial spin labeling; CBF, cerebral blood flow; CN, cognitively normal; FDG, fluorodeoxyglucose; FLAIR, fluidāattenuated inversion recovery; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; PET, positron emission tomography; WMH, white matter hyperintensity
Apoliprotein E ε4 (APOE4) is the primary genetic risk factor for the late-onset, sporadic form of Alzheimerās disease (AD). As such, researchers have extensively investigated the reasons why APOE4 increases an individualās susceptibility to AD. However, much less research has been conducted to identify the differences in disease presentation that occur between APOE4 carriers vs. non-carriers. To help address this topic, we performed a comprehensive analysis of neuroimaging biomarkers in the brains of APOE4 carriers vs. non-carriers who participated in the Alzheimerās Disease Neuroimaging Initiative (ADNI). Specifically, we processed ADNI data from six neuroimaging biomarkers: florbetapir positron emission tomography (PET) measurements of amyloid beta (Aβ) deposition, flortaucipir PET measurements of tau accumulation, fluorodeoxyglucose (FDG) PET measurements of glucose uptake, structural magnetic resonance imaging (MRI) measurements of brain volume, arterial spin labeling (ASL) MRI measurements of cerebral blood flow (CBF), and fluidāattenuated inversion recovery (FLAIR) MRI measurements of white matter hyperintensities (WMHs). Furthermore, we compared the regional levels of each of these biomarkers in APOE4 carriers vs. non-carriers at three separate ADNI-determined diagnostic stages: cognitively normal (CN), mild cognitive impairment (MCI), and AD. The analysis was conducted under my supervision and primarily performed by Jason Mares, a highly skilled bioinformatician in Dr. Vilas Menonās group.
Overall, we observed extensive heterogeneity in how these neuroimaging biomarkers present in the brains of APOE4 carriers vs. non-carriers. In particular, we observed robust APOE4āassociated increases in Aβ deposition throughout the brain, in all three diagnostic groups. We also observed APOE4āassociated increases in tau pathology, decreases in glucose uptake, and increases in brain atrophy, which expanded in regional scope and magnitude with disease progression. Significant sexā and ageārelated differences in APOE4āassociated neuroimaging biomarker heterogeneity were also observed, with female APOE4 carriers displaying notable increases in pathological presentation for a variety of biomarkers. Lastly, specific regional differences in Aβ deposition, tau accumulation, glucose uptake, ventricle size, and white matter hyperintensities were observed in CN participants who converted to MCI/AD during their participation in ADNI, which we showed may hold potential predictive value for determining the likelihood of MCI/AD conversion among cognitively unimpaired individuals.
Our study highlights the need for genotype-specific approaches in AD diagnostics and interventions, given the clear biological heterogeneity associated with an individualās APOE4 status.
Tal Nuriel, PhD
Assistant Professor of Pathology and Cell Biology (in the Taub Institute) at CUMC
tn2283@cumc.columbia.edu
